Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA
NCT00959504 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 275
Last updated 2011-06-09
Summary
As an external validation test of the performance of the VeraCode Genotyping Test for Factor V and Factor II on the BeadXpress System, clinical trials will be conducted at three sites. This study will assess genotyping accuracy as compared to bidirectional sequencing and genotyping reproducibility across variables such as user, day, and site.
Conditions
- Detection and Genotyping of Factor V and Factor II Point Mutations
Sponsors & Collaborators
-
Illumina, Inc.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-08-31
- Primary Completion
- 2009-09-30
- Completion
- 2009-09-30
More Related Trials
-
Study to Test the Accuracy of a Prototype Handheld PT/INR Device
NCT01349712 ·Status: UNKNOWN
-
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications
NCT00603148 ·Status: COMPLETED
-
Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis
NCT02078154 ·Status: TERMINATED
-
Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
NCT01809054 ·Status: COMPLETED ·Phase: PHASE4
-
New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".
NCT02841085 ·Status: COMPLETED
-
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
NCT06292117 ·Status: RECRUITING
-
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
NCT00830570 ·Status: COMPLETED
-
Fiix-prothrombin Time for Monitoring Warfarin
NCT01565239 ·Status: COMPLETED ·Phase: PHASE2
-
Risk Factors for Venous Thromboembolism in the Community
NCT00011180 ·Status: COMPLETED
-
Predictors of Anticoagulation Control on Warfarin Therapy
NCT00905177 ·Status: COMPLETED
-
Vorapaxar and Lower Extremity Bypass Grafts
NCT02975583 ·Status: WITHDRAWN ·Phase: PHASE4
-
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
NCT02704052 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Vascular Trial Associated Registry Pilot
NCT07076082 ·Status: RECRUITING ·Phase: PHASE4
-
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
NCT03682419 ·Status: COMPLETED ·Phase: NA
-
Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome
NCT00395265 ·Status: COMPLETED
-
Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing
NCT00484640 ·Status: UNKNOWN ·Phase: NA
-
Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
NCT02022020 ·Status: COMPLETED
-
Clinical and Economic Implications of Genetic Testing for Warfarin Management
NCT00964353 ·Status: COMPLETED ·Phase: PHASE4
-
A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay
NCT04737954 ·Status: UNKNOWN ·Phase: NA
-
Epidemiology of Venous Thrombosis and Pulmonary Embolism
NCT00005504 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Point of Care to Lab INR in Dialysis Patients on Warfarin
NCT00660946 ·Status: COMPLETED
-
Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer
NCT03180567 ·Status: UNKNOWN ·Phase: NA
-
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
NCT03083704 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
NCT00443053 ·Status: COMPLETED ·Phase: PHASE3
-
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
NCT01420809 ·Status: COMPLETED